SplitMay 4, 2026, 04:18 PM
Ernexa Therapeutics Completes 1-for-25 Reverse Stock Split
AI Summary
Ernexa Therapeutics Inc. implemented a 1-for-25 reverse stock split, effective May 4, 2026. The company filed a certificate of amendment to its Restated Certificate of Incorporation on May 1, 2026, to enact this change. Following the split, the common stock commenced trading on a split-adjusted basis on Nasdaq under a new CUSIP number.
Key Highlights
- Ernexa Therapeutics Inc. filed a certificate of amendment for a 1-for-25 reverse stock split.
- The reverse stock split became effective at market open on May 4, 2026.
- Common stock began trading on a split-adjusted basis on Nasdaq.
- The new CUSIP number for the common stock is 114082407.